tumor regression cancer patients low doses t cell-engaging antibody
previous attempts shown potential t cells immunotherapy cancer report clinical activity bispecific antibody construct called blinatumomab potential engage cytotoxic t cells patients lysis cancer cells doses low milligrams per square meter per day non hodgkins lymphoma patients led elimination target cells blood partial complete tumor regressions first observed dose level milligrams seven patients treated dose level milligrams experienced tumor regression blinatumomab also led clearance tumor cells bone marrow liver t cell engaging antibodies appear therapeutic potential treatment malignant diseases
